Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy
Expand clinical literature on the use of Grid radiation with conventional external beam therapy. Vast majority of therapy is for palliative care to provide relief from pain, but has also shown a reduction in the size of tumor mass.
Checked against the public recordLast updated May 18, 2015 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Summa Health System
- Interventions being studied
- Radiation: Spatially Fractioned Radiation Therapy; Radiation: Treatment Group 1; Radiation: Standard radiation; Radiation: Standard radiation
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Patients with histologic or cytologic diagnosis of primary or metastatic epithelial cancer or sarcoma located in the head and neck area, lung, abdomen or pelvis. * Tumors must have an overall dimension greater than 24 cm2 (bidimensional) with one dimensions \>6 cm, by x-ray, CT/MRI scan or clinical exam. * Age \>18 * Karnofsky \> 70 with life expectancy \>3 months. * Patients may not begin new hormone therapy within 2 weeks of initiation of protocol treatment. * No planned initiation of hormone therapy within 2 weeks of protocol therapy * Adequate bone marrow function: Hb \> 9, white blood cell count (WBC) \> 2,000. Hepatic function \< 3x upper limit of laboratory normal values. * Laboratory studies will be obtained within 2 weeks prior to randomization. * Patients with metastatic sites of disease including brain are eligible provided that life expectancy is \> 3 months. Exclusion Criteria: * Hematologic-related tumors. * Tumors overlying critical central nervous system structures including spinal cord, eye or brainstem or require treatment portals over these vital structures. * Central nervous system tumors * Evidence of other primary malignancy except for carcinoma in situ of cervix or skin cancer excluding melanoma unless disease free for 2 years prior to randomization * Patients with spinal cord compression. * Prior radiation to treatment field. * Concomitant chemotherapy or chemotherapy within past 2 weeks. Planned initiation of chemotherapy within 2 weeks of completing protocol treatment
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Summa Health SystemAkron, Ohio
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 18, 2015. Always confirm current availability with the study team.